Amgen (Nasdaq: AMGN) announced results from new analyses comparing XGEVA? (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid)...
More...